The company has not filed an annual or quarterly report since its FY2017 10-K, filed Aug 29, 2017. Its latest SEC filing is a SC 13G/A from Feb 13, 2018.
10-K for FY2017, filed Aug 29, 2017
The sections below describe the company as of the FY2017 annual report.
Manages clinical trials and related research services for pharmaceutical, biotechnology, and medical-device companies, and provides consulting and technology solutions to those industries.
10-K for FY2017, filed Aug 29, 2017We provide broad expertise in clinical research, medical communications, consulting, commercialization and advanced technology services to…View ↗
CRS constitutes our core business and includes all phases of clinical research from Early Phase (encompassing the early stages of clinical…View ↗
CRS offers complete services for the design, initiation, and management of clinical trial programs, a critical element in obtaining…View ↗
Clients pay for clinical research and consulting services under fee-for-service or fixed-price contracts, typically with a down payment and later installments tied to milestones; payments come as projects progress.
10-K for FY2017, filed Aug 29, 2017The majority of our contracts are fixed price, with some variable components, and range in duration from a few months to several years.…View ↗
Service revenue in our CRS and PC businesses are derived principally from fee-for-service or fixed-price executory contracts, which…View ↗
We recognize revenue for the separate elements of our contracts upon delivery of actual units of output and when all other revenue…View ↗
$2.4B
10-K for FY2017, filed Aug 30, 2017
$2.4B ↗
Pharmaceutical, biotechnology, and medical-device companies hire PAREXEL for research and commercialization services; its business-development teams prepare proposals and manage client relationships, coordinating across segments when needed.
10-K for FY2017, filed Aug 29, 2017Our services complement the research and development (“R&D”) and marketing functions of pharmaceutical, biotechnology, diagnostics, and…View ↗
Our sales and marketing personnel carry out our global business development activities. In addition to significant selling experience, most…View ↗
Each of our three reporting segments has a business development team that focuses on its particular market segment. In many cases, however…View ↗
Each business development employee is responsible for a specific client segment or group of clients and for strengthening and expanding an…View ↗
10-K for FY2017, filed Aug 29, 2017
We perform ongoing credit evaluations related to the financial condition of our clients and, generally, do not require collateral. As of…View ↗
Yes. It kept 4 cents of every revenue dollar as net income in FY2017 and turned 10 cents into free cash flow.
10-K for FY2017, filed Aug 30, 2017
10-K for FY2017, filed Aug 30, 2017
$191.2MView ↗
10-K for FY2017, filed Aug 30, 2017
$107.3MView ↗
10-K for FY2017, filed Aug 30, 2017
$233.8MView ↗
8-K, filed Sep 29, 2017
BOSTON, September 29, 2017 - PAREXEL International Corporation (NASDAQ: PRXL) (“PAREXEL” or the “Company”), a leading global…View ↗
Grew. Revenue grew 22% in 4 years, from $2B in FY2013 to $2.4B in FY2017, about 5% a year.
Competes with QuintilesIMS, Laboratory Corporation of America, Pharmaceutical Product Development, INC Research, inVentiv Health, PRA Health Sciences, and Icon
10-K for FY2017, filed Aug 29, 2017We compete with other biopharmaceutical outsourcing services companies and other clinical research organizations (“CROs”) that provide one…View ↗
Loading...
